25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Enliven Therapeutics Inc.
Buy, Hold or Sell?

Let's analyze Enliven Therapeutics Inc. together

I guess you are interested in Enliven Therapeutics Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enliven Therapeutics Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Enliven Therapeutics Inc.

I send you an email if I find something interesting about Enliven Therapeutics Inc..

1. Quick Overview

1.1. Quick analysis of Enliven Therapeutics Inc. (30 sec.)










1.2. What can you expect buying and holding a share of Enliven Therapeutics Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.01
Expected worth in 1 year
$-5.35
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$-5.35
Return On Investment
-21.1%

For what price can you sell your share?

Current Price per Share
$25.41
Expected price per share
$23.70 - $30.03
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Enliven Therapeutics Inc. (5 min.)




Live pricePrice per Share (EOD)
$25.41
Intrinsic Value Per Share
$3.23 - $4.31
Total Value Per Share
$3.24 - $4.31

2.2. Growth of Enliven Therapeutics Inc. (5 min.)




Is Enliven Therapeutics Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$288.4m$230.5m$58.6m20.3%

How much money is Enliven Therapeutics Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$21.3m-$4.5m-$16.7m-78.5%
Net Profit Margin-1,100.6%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Enliven Therapeutics Inc. (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Enliven Therapeutics Inc.?

Welcome investor! Enliven Therapeutics Inc.'s management wants to use your money to grow the business. In return you get a share of Enliven Therapeutics Inc..

First you should know what it really means to hold a share of Enliven Therapeutics Inc.. And how you can make/lose money.

Speculation

The Price per Share of Enliven Therapeutics Inc. is $25.41. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enliven Therapeutics Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enliven Therapeutics Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.01. Based on the TTM, the Book Value Change Per Share is $-1.34 per quarter. Based on the YOY, the Book Value Change Per Share is $1.69 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enliven Therapeutics Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.000.0%-0.32-1.3%-0.34-1.3%-0.26-1.0%-0.26-1.0%
Usd Book Value Change Per Share-6.24-24.5%-1.34-5.3%1.696.6%0.000.0%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-6.24-24.5%-1.34-5.3%1.696.6%0.000.0%0.000.0%
Usd Price Per Share25.54-20.09-15.02-12.73-12.73-
Price to Earnings Ratio-13,309.19--3,335.42--11.13--676.05--676.05-
Price-to-Total Gains Ratio-4.10--31.04--28.10-38.14-38.14-
Price to Book Ratio4,274.40-1,070.90-3.00-217.52-217.52-
Price-to-Total Gains Ratio-4.10--31.04--28.10-38.14-38.14-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share25.41
Number of shares39
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-1.340.00
Usd Total Gains Per Share-1.340.00
Gains per Quarter (39 shares)-52.170.01
Gains per Year (39 shares)-208.700.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-209-21900-10
20-417-42800-10
30-626-63700-10
40-835-84600-10
50-1043-105500-10
60-1252-126400-10
70-1461-147300-10
80-1670-168200-10
90-1878-189100-10
100-2087-210000-10

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.020.00.00.0%0.020.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%8.012.00.040.0%8.012.00.040.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%8.012.00.040.0%8.012.00.040.0%8.012.00.040.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Enliven Therapeutics Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---6.235-1.338-79%1.688-469%0.000-2087114%0.000-2087114%
Book Value Per Share--0.0064.446-100%4.719-100%2.531-100%2.531-100%
Current Ratio--17.44313.896+26%32.353-46%18.514-6%18.514-6%
Debt To Asset Ratio--0.0560.073-24%0.034+65%0.216-74%0.216-74%
Debt To Equity Ratio--0.0590.079-25%0.035+68%0.065-9%0.065-9%
Dividend Per Share----0%-0%-0%-0%
Eps--0.000-0.318+66113%-0.343+71293%-0.257+53484%-0.257+53484%
Free Cash Flow Per Share---0.001-0.288+23017%-0.260+20773%-0.223+17789%-0.223+17789%
Free Cash Flow To Equity Per Share--0.0010.184-100%0.932-100%0.256-100%0.256-100%
Gross Profit Margin--1.0001.0000%0.976+2%0.996+0%0.996+0%
Intrinsic Value_10Y_max--4.307--------
Intrinsic Value_10Y_min--3.230--------
Intrinsic Value_1Y_max---0.746--------
Intrinsic Value_1Y_min---0.733--------
Intrinsic Value_3Y_max---1.344--------
Intrinsic Value_3Y_min---1.301--------
Intrinsic Value_5Y_max---0.860--------
Intrinsic Value_5Y_min---0.875--------
Market Cap1241512272.000-99194%1232750877320.000308857090370.000+299%733620888.000+167937%62196883987.600+1882%62196883987.600+1882%
Net Profit Margin----11.0060%-0%-2.2010%-2.2010%
Operating Margin----12.9140%-0%-2.5830%-2.5830%
Operating Ratio---12.914-100%-0%2.583-100%2.583-100%
Pb Ratio4252.647-1%4274.4041070.901+299%3.003+142224%217.523+1865%217.523+1865%
Pe Ratio-13241.450+1%-13309.195-3335.420-75%-11.126-100%-676.053-95%-676.053-95%
Price Per Share25.410-1%25.54020.085+27%15.015+70%12.725+101%12.725+101%
Price To Free Cash Flow Ratio-5090.971+1%-5117.017-1288.426-75%-17.265-100%-268.537-95%-268.537-95%
Price To Total Gains Ratio-4.075+1%-4.096-31.039+658%-28.100+586%38.141-111%38.141-111%
Quick Ratio--28.36921.898+30%39.854-29%24.800+14%24.800+14%
Return On Assets---0.076-0.069-10%0.043-275%-0.080+5%-0.080+5%
Return On Equity---0.080-0.074-8%0.043-286%-0.077-4%-0.077-4%
Total Gains Per Share---6.235-1.338-79%1.688-469%0.000-2087114%0.000-2087114%
Usd Book Value--288403000.000289238250.0000%230571750.000+25%138075250.000+109%138075250.000+109%
Usd Book Value Change Per Share---6.235-1.338-79%1.688-469%0.000-2087114%0.000-2087114%
Usd Book Value Per Share--0.0064.446-100%4.719-100%2.531-100%2.531-100%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.000-0.318+66113%-0.343+71293%-0.257+53484%-0.257+53484%
Usd Free Cash Flow---60228000.000-29135500.000-52%-12725750.000-79%-13914750.000-77%-13914750.000-77%
Usd Free Cash Flow Per Share---0.001-0.288+23017%-0.260+20773%-0.223+17789%-0.223+17789%
Usd Free Cash Flow To Equity Per Share--0.0010.184-100%0.932-100%0.256-100%0.256-100%
Usd Market Cap1241512272.000-99194%1232750877320.000308857090370.000+299%733620888.000+167937%62196883987.600+1882%62196883987.600+1882%
Usd Price Per Share25.410-1%25.54020.085+27%15.015+70%12.725+101%12.725+101%
Usd Profit---23156000.000-21303500.000-8%-4583750.000-80%-11286400.000-51%-11286400.000-51%
Usd Revenue---110000.000-100%-0%22000.000-100%22000.000-100%
Usd Total Gains Per Share---6.235-1.338-79%1.688-469%0.000-2087114%0.000-2087114%
 EOD+3 -5MRQTTM+15 -16YOY+12 -185Y+16 -1610Y+16 -16

3.3 Fundamental Score

Let's check the fundamental score of Enliven Therapeutics Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13,241.450
Price to Book Ratio (EOD)Between0-14,252.647
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than128.369
Current Ratio (MRQ)Greater than117.443
Debt to Asset Ratio (MRQ)Less than10.056
Debt to Equity Ratio (MRQ)Less than10.059
Return on Equity (MRQ)Greater than0.15-0.080
Return on Assets (MRQ)Greater than0.05-0.076
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Enliven Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.693
Ma 20Greater thanMa 5026.484
Ma 50Greater thanMa 10026.708
Ma 100Greater thanMa 20024.918
OpenGreater thanClose24.450
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Enliven Therapeutics Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Fundamental data was last updated by Penke on 2024-11-20 22:22:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Enliven Therapeutics Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enliven Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,100.6%+1,100.6%
TTM-1,100.6%YOY--1,100.6%
TTM-1,100.6%5Y-220.1%-880.5%
5Y-220.1%10Y-220.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--113.9%+113.9%
TTM-1,100.6%-214.4%-886.2%
YOY--210.0%+210.0%
5Y-220.1%-339.1%+119.0%
10Y-220.1%-464.5%+244.4%
4.3.1.2. Return on Assets

Shows how efficient Enliven Therapeutics Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • -7.6% Return on Assets means that Enliven Therapeutics Inc. generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enliven Therapeutics Inc.:

  • The MRQ is -7.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-6.9%-0.7%
TTM-6.9%YOY4.3%-11.2%
TTM-6.9%5Y-8.0%+1.1%
5Y-8.0%10Y-8.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-11.1%+3.5%
TTM-6.9%-11.7%+4.8%
YOY4.3%-11.3%+15.6%
5Y-8.0%-12.7%+4.7%
10Y-8.0%-14.3%+6.3%
4.3.1.3. Return on Equity

Shows how efficient Enliven Therapeutics Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • -8.0% Return on Equity means Enliven Therapeutics Inc. generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enliven Therapeutics Inc.:

  • The MRQ is -8.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.0%TTM-7.4%-0.6%
TTM-7.4%YOY4.3%-11.7%
TTM-7.4%5Y-7.7%+0.3%
5Y-7.7%10Y-7.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.0%-14.2%+6.2%
TTM-7.4%-15.8%+8.4%
YOY4.3%-14.2%+18.5%
5Y-7.7%-18.5%+10.8%
10Y-7.7%-19.5%+11.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Enliven Therapeutics Inc..

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Enliven Therapeutics Inc. is operating .

  • Measures how much profit Enliven Therapeutics Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enliven Therapeutics Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,291.4%+1,291.4%
TTM-1,291.4%YOY--1,291.4%
TTM-1,291.4%5Y-258.3%-1,033.1%
5Y-258.3%10Y-258.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--224.9%+224.9%
TTM-1,291.4%-306.4%-985.0%
YOY--223.5%+223.5%
5Y-258.3%-386.5%+128.2%
10Y-258.3%-497.6%+239.3%
4.3.2.2. Operating Ratio

Measures how efficient Enliven Therapeutics Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Enliven Therapeutics Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM12.914-12.914
TTM12.914YOY-+12.914
TTM12.9145Y2.583+10.331
5Y2.58310Y2.5830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.508-2.508
TTM12.9143.295+9.619
YOY-3.298-3.298
5Y2.5834.788-2.205
10Y2.5836.517-3.934
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Enliven Therapeutics Inc..

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Enliven Therapeutics Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 17.44 means the company has $17.44 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Enliven Therapeutics Inc.:

  • The MRQ is 17.443. The company is very able to pay all its short-term debts. +2
  • The TTM is 13.896. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ17.443TTM13.896+3.547
TTM13.896YOY32.353-18.457
TTM13.8965Y18.514-4.618
5Y18.51410Y18.5140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ17.4433.645+13.798
TTM13.8963.877+10.019
YOY32.3534.666+27.687
5Y18.5145.938+12.576
10Y18.5146.265+12.249
4.4.3.2. Quick Ratio

Measures if Enliven Therapeutics Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 28.37 means the company can pay off $28.37 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enliven Therapeutics Inc.:

  • The MRQ is 28.369. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 21.898. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ28.369TTM21.898+6.472
TTM21.898YOY39.854-17.956
TTM21.8985Y24.800-2.903
5Y24.80010Y24.8000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.3693.093+25.276
TTM21.8983.432+18.466
YOY39.8544.478+35.376
5Y24.8005.927+18.873
10Y24.8006.424+18.376
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Enliven Therapeutics Inc..

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Enliven Therapeutics Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enliven Therapeutics Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Enliven Therapeutics Inc. assets are financed with 5.6% credit (debt) and the remaining percentage (100% - 5.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enliven Therapeutics Inc.:

  • The MRQ is 0.056. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.073. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.056TTM0.073-0.017
TTM0.073YOY0.034+0.039
TTM0.0735Y0.216-0.143
5Y0.21610Y0.2160.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0560.354-0.298
TTM0.0730.345-0.272
YOY0.0340.311-0.277
5Y0.2160.366-0.150
10Y0.2160.383-0.167
4.5.4.2. Debt to Equity Ratio

Measures if Enliven Therapeutics Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 5.9% means that company has $0.06 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enliven Therapeutics Inc.:

  • The MRQ is 0.059. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.079. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.059TTM0.079-0.020
TTM0.079YOY0.035+0.044
TTM0.0795Y0.065+0.014
5Y0.06510Y0.0650.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0590.396-0.337
TTM0.0790.436-0.357
YOY0.0350.380-0.345
5Y0.0650.451-0.386
10Y0.0650.493-0.428
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Enliven Therapeutics Inc. generates.

  • Above 15 is considered overpriced but always compare Enliven Therapeutics Inc. to the Biotechnology industry mean.
  • A PE ratio of -13,309.19 means the investor is paying $-13,309.19 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enliven Therapeutics Inc.:

  • The EOD is -13,241.450. Based on the earnings, the company is expensive. -2
  • The MRQ is -13,309.195. Based on the earnings, the company is expensive. -2
  • The TTM is -3,335.420. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13,241.450MRQ-13,309.195+67.745
MRQ-13,309.195TTM-3,335.420-9,973.775
TTM-3,335.420YOY-11.126-3,324.294
TTM-3,335.4205Y-676.053-2,659.367
5Y-676.05310Y-676.0530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13,241.450-2.220-13,239.230
MRQ-13,309.195-2.398-13,306.797
TTM-3,335.420-3.148-3,332.272
YOY-11.126-3.237-7.889
5Y-676.053-6.033-670.020
10Y-676.053-6.685-669.368
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enliven Therapeutics Inc.:

  • The EOD is -5,090.971. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5,117.017. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1,288.426. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5,090.971MRQ-5,117.017+26.046
MRQ-5,117.017TTM-1,288.426-3,828.592
TTM-1,288.426YOY-17.265-1,271.160
TTM-1,288.4265Y-268.537-1,019.889
5Y-268.53710Y-268.5370.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5,090.971-2.988-5,087.983
MRQ-5,117.017-3.276-5,113.741
TTM-1,288.426-3.734-1,284.692
YOY-17.265-4.523-12.742
5Y-268.537-8.321-260.216
10Y-268.537-9.273-259.264
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Enliven Therapeutics Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4,274.40 means the investor is paying $4,274.40 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Enliven Therapeutics Inc.:

  • The EOD is 4,252.647. Based on the equity, the company is expensive. -2
  • The MRQ is 4,274.404. Based on the equity, the company is expensive. -2
  • The TTM is 1,070.901. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4,252.647MRQ4,274.404-21.757
MRQ4,274.404TTM1,070.901+3,203.503
TTM1,070.901YOY3.003+1,067.898
TTM1,070.9015Y217.523+853.378
5Y217.52310Y217.5230.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4,252.6471.894+4,250.753
MRQ4,274.4042.027+4,272.377
TTM1,070.9012.356+1,068.545
YOY3.0032.418+0.585
5Y217.5233.686+213.837
10Y217.5234.357+213.166
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Enliven Therapeutics Inc..

4.8.3. Insider Transactions

Insiders are holding 6.393% of the shares of Enliven Therapeutics Inc..

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-28Benjamin HohlSELL625028.56
2024-10-18Anish PatelSELL71630
2024-10-18Benjamin HohlSELL81430
2024-10-18Joseph P LyssikatosSELL84730
2024-10-18Richard A HeymanSELL81730
2024-10-18Samuel KintzSELL92430
2024-10-15Richard A HeymanSELL127027.67
2024-10-09Joseph P LyssikatosSELL3787828.16
2024-10-09Samuel KintzSELL1671028.15
2024-10-08Rahul D BallalSELL1042028.17
2024-10-07Benjamin HohlSELL127027.51
2024-10-07Samuel KintzSELL273027.5
2024-10-07Joseph P LyssikatosSELL270727.61
2024-10-04Benjamin HohlSELL1021827.51
2024-10-04Joseph P LyssikatosSELL752227.51
2024-10-04Richard A HeymanSELL282527.51
2024-10-04Samuel KintzSELL1220627.51
2024-10-01Joseph P LyssikatosSELL52727.54
2024-10-01Richard A HeymanSELL51827.54
2024-10-01Samuel KintzSELL52627.54
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets305,430
Total Liabilities17,027
Total Stockholder Equity288,403
 As reported
Total Liabilities 17,027
Total Stockholder Equity+ 288,403
Total Assets = 305,430

Assets

Total Assets305,430
Total Current Assets296,997
Long-term Assets8,433
Total Current Assets
Cash And Cash Equivalents 100,621
Short-term Investments 191,213
Other Current Assets 5,163
Total Current Assets  (as reported)296,997
Total Current Assets  (calculated)296,997
+/-0
Long-term Assets
Property Plant Equipment 630
Long-term Assets Other 7,803
Long-term Assets  (as reported)8,433
Long-term Assets  (calculated)8,433
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities17,027
Long-term Liabilities0
Total Stockholder Equity288,403
Total Current Liabilities
Accounts payable 1,019
Other Current Liabilities 16,008
Total Current Liabilities  (as reported)17,027
Total Current Liabilities  (calculated)17,027
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock47
Retained Earnings -220,292
Accumulated Other Comprehensive Income 242
Other Stockholders Equity 508,406
Total Stockholder Equity (as reported)288,403
Total Stockholder Equity (calculated)288,403
+/-0
Other
Cash and Short Term Investments 291,834
Common Stock Shares Outstanding 48,267,458
Liabilities and Stockholders Equity 305,430
Net Debt -100,621
Net Working Capital 279,970



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
33,298
110,322
111,317
100,175
90,842
81,687
72,468
107,027
113,329
81,602
64,666
90,795
91,959
302,866
288,501
274,041
271,867
342,777
327,043
305,430
305,430327,043342,777271,867274,041288,501302,86691,95990,79564,66681,602113,329107,02772,46881,68790,842100,175111,317110,32233,298000
   > Total Current Assets 
0
0
0
30,624
109,816
110,593
99,711
90,405
80,361
71,357
105,997
110,670
78,528
64,256
88,229
89,636
298,003
283,175
268,606
266,151
337,199
318,127
296,997
296,997318,127337,199266,151268,606283,175298,00389,63688,22964,25678,528110,670105,99771,35780,36190,40599,711110,593109,81630,624000
       Cash And Cash Equivalents 
0
0
0
4,936
86,722
54,651
34,158
47,698
53,441
48,037
75,295
110,024
36,484
30,433
86,159
88,198
292,102
125,715
73,847
100,195
149,219
96,871
100,621
100,62196,871149,219100,19573,847125,715292,10288,19886,15930,43336,484110,02475,29548,03753,44147,69834,15854,65186,7224,936000
       Short-term Investments 
0
0
0
23,971
19,145
51,624
61,931
40,524
22,151
18,731
27,544
41,969
36,416
29,907
6,813
0
0
152,150
189,631
153,007
171,339
215,519
191,213
191,213215,519171,339153,007189,631152,150006,81329,90736,41641,96927,54418,73122,15140,52461,93151,62419,14523,971000
       Other Current Assets 
0
0
0
1,717
3,949
4,318
3,622
2,183
4,769
4,589
3,158
646
5,628
3,916
2,070
1,438
5,901
5,310
5,128
13,003
16,695
5,737
5,163
5,1635,73716,69513,0035,1285,3105,9011,4382,0703,9165,6286463,1584,5894,7692,1833,6224,3183,9491,717000
   > Long-term Assets 
0
0
0
2,674
506
724
464
437
1,326
1,111
1,030
2,659
3,074
410
2,566
2,323
4,863
5,326
5,435
5,716
5,578
8,916
8,433
8,4338,9165,5785,7165,4355,3264,8632,3232,5664103,0742,6591,0301,1111,3264374647245062,674000
       Property Plant Equipment 
0
0
0
442
418
400
376
349
1,018
936
855
954
2,899
235
1,553
1,516
1,404
1,342
1,204
1,062
924
791
630
6307919241,0621,2041,3421,4041,5161,5532352,8999548559361,018349376400418442000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-2,566
0
3,459
0
0
0
0
0
0
0000003,4590-2,56600000000000000
> Total Liabilities 
0
0
0
4,382
5,128
5,021
5,477
6,407
6,093
7,501
7,654
156,216
9,190
3,302
158,892
1,830
11,450
9,507
12,293
25,961
25,065
22,111
17,027
17,02722,11125,06525,96112,2939,50711,4501,830158,8923,3029,190156,2167,6547,5016,0936,4075,4775,0215,1284,382000
   > Total Current Liabilities 
0
0
0
4,198
4,949
4,848
5,310
6,247
5,503
6,973
7,188
5,753
7,223
3,302
8,333
1,830
10,942
9,147
12,079
25,894
25,031
22,105
17,027
17,02722,10525,03125,89412,0799,14710,9421,8308,3333,3027,2235,7537,1886,9735,5036,2475,3104,8484,9494,198000
       Short-term Debt 
0
0
0
0
0
0
0
0
257
254
250
159
508
445
320
323
326
329
332
335
252
169
0
016925233533232932632332044550815925025425700000000
       Accounts payable 
0
0
0
1,658
2,322
1,669
1,886
1,971
3,001
2,626
2,476
2,521
1,884
1,135
2,993
149
5,860
2,843
1,493
532
2,727
1,083
1,019
1,0191,0832,7275321,4932,8435,8601492,9931,1351,8842,5212,4762,6263,0011,9711,8861,6692,3221,658000
       Other Current Liabilities 
0
0
0
2,540
2,627
3,179
3,424
4,276
2,245
4,093
4,462
370
4,831
1,722
5,020
1,681
4,756
343
-1,125
25,027
22,052
20,621
16,008
16,00820,62122,05225,027-1,1253434,7561,6815,0201,7224,8313704,4624,0932,2454,2763,4243,1792,6272,540000
   > Long-term Liabilities 
0
0
0
184
179
173
167
160
590
528
466
150,463
1,967
1,580
150,559
150,408
508
360
214
67
34
6
0
063467214360508150,408150,5591,5801,967150,463466528590160167173179184000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
508
360
0
0
0
0
0
000003605080000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
524
0
0
0
0
0
0000052400000000000000000
> Total Stockholder Equity
0
0
0
28,916
105,194
106,296
94,698
84,435
75,594
64,967
99,373
-42,887
72,412
61,364
-68,097
90,129
291,416
278,994
261,748
245,906
317,712
304,932
288,403
288,403304,932317,712245,906261,748278,994291,41690,129-68,09761,36472,412-42,88799,37364,96775,59484,43594,698106,296105,19428,916000
   Common Stock
0
0
0
10
17
18
18
18
18
19
27
1
27
27
1
27
41
41
41
41
47
47
47
47474741414141271272712719181818181710000
   Retained Earnings Total Equity00000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
32
-16
48
24
4
1
0
-2
-16
-51
-35
-4
-177
0
-111
-147
141
-53
-139
242
242-139-53141-147-1110-177-4-35-51-16-20142448-1632000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
0
83,627
167,161
178,402
179,251
180,526
181,945
184,479
232,526
-147,419
84,823
234,957
5,070
236,138
388,963
393,373
396,932
400,172
494,904
502,160
508,406
508,406502,160494,904400,172396,932393,373388,963236,1385,070234,95784,823-147,419232,526184,479181,945180,526179,251178,402167,16183,627000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-297
Gross Profit-297-297
 
Operating Income (+$)
Gross Profit-297
Operating Expense-83,529
Operating Income-83,529-83,826
 
Operating Expense (+$)
Research Development64,574
Selling General Administrative18,955
Selling And Marketing Expenses18,937
Operating Expense83,529102,466
 
Net Interest Income (+$)
Interest Income11,967
Interest Expense-0
Other Finance Cost-0
Net Interest Income11,967
 
Pretax Income (+$)
Operating Income-83,529
Net Interest Income11,967
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-71,584-95,474
EBIT - interestExpense = -82,229
-70,284
-71,584
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-82,229-71,584
Earnings Before Interest and Taxes (EBITDA)-81,932
 
After tax Income (+$)
Income Before Tax-71,584
Tax Provision-0
Net Income From Continuing Ops-71,584-71,584
Net Income-71,584
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses83,529
Total Other Income/Expenses Net11,945-11,967
 

Technical Analysis of Enliven Therapeutics Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enliven Therapeutics Inc.. The general trend of Enliven Therapeutics Inc. is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enliven Therapeutics Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enliven Therapeutics Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 26.91 < 29.79 < 30.03.

The bearish price targets are: 24.28 > 24.18 > 23.70.

Tweet this
Enliven Therapeutics Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enliven Therapeutics Inc.. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enliven Therapeutics Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enliven Therapeutics Inc.. The current macd is -0.67553555.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Enliven Therapeutics Inc. price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Enliven Therapeutics Inc.. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Enliven Therapeutics Inc. price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Enliven Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) ChartEnliven Therapeutics Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enliven Therapeutics Inc.. The current adx is 23.63.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Enliven Therapeutics Inc. shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Enliven Therapeutics Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enliven Therapeutics Inc.. The current sar is 26.55.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Enliven Therapeutics Inc. Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enliven Therapeutics Inc.. The current rsi is 44.69. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
Enliven Therapeutics Inc. Daily Relative Strength Index (RSI) ChartEnliven Therapeutics Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enliven Therapeutics Inc.. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Enliven Therapeutics Inc. price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Enliven Therapeutics Inc. Daily Stochastic Oscillator ChartEnliven Therapeutics Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enliven Therapeutics Inc.. The current cci is -61.72400874.

Enliven Therapeutics Inc. Daily Commodity Channel Index (CCI) ChartEnliven Therapeutics Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enliven Therapeutics Inc.. The current cmo is -9.45872582.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Enliven Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) ChartEnliven Therapeutics Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enliven Therapeutics Inc.. The current willr is -70.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Enliven Therapeutics Inc. is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Enliven Therapeutics Inc. Daily Williams %R ChartEnliven Therapeutics Inc. Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enliven Therapeutics Inc..

Enliven Therapeutics Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enliven Therapeutics Inc.. The current atr is 1.34703943.

Enliven Therapeutics Inc. Daily Average True Range (ATR) ChartEnliven Therapeutics Inc. Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enliven Therapeutics Inc.. The current obv is -415,619.

Enliven Therapeutics Inc. Daily On-Balance Volume (OBV) ChartEnliven Therapeutics Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enliven Therapeutics Inc.. The current mfi is 28.72.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Enliven Therapeutics Inc. Daily Money Flow Index (MFI) ChartEnliven Therapeutics Inc. Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enliven Therapeutics Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-01STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-08-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-09-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-10-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-10-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Enliven Therapeutics Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enliven Therapeutics Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5044.693
Ma 20Greater thanMa 5026.484
Ma 50Greater thanMa 10026.708
Ma 100Greater thanMa 20024.918
OpenGreater thanClose24.450
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Enliven Therapeutics Inc. with someone you think should read this too:
  • Are you bullish or bearish on Enliven Therapeutics Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enliven Therapeutics Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enliven Therapeutics Inc.

I send you an email if I find something interesting about Enliven Therapeutics Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Enliven Therapeutics Inc..

Receive notifications about Enliven Therapeutics Inc. in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.